509 results
Page 4 of 26
CORRESP
y9e50icji
6 Jan 21
Correspondence with SEC
12:00am
UPLOAD
yzu80djp
23 Dec 20
Letter from SEC
12:00am
8-K
EX-99.1
apk66d42mchdc1buwl5
21 Dec 20
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
8:39am
8-K/A
EX-99.1
plapc3ns7o6qxcql
10 Dec 20
Financial Statements and Exhibits
4:13pm
8-K
6e00pqgjk6vz9dmq kd
3 Dec 20
Other Events
12:00am
8-K
0x5bkgnse
23 Nov 20
Other Events
8:32am
8-K
12zneeg2o4aj61dae uf
30 Oct 20
Amendments to Articles of Incorporation or Bylaws
4:07pm
8-K
EX-99.1
jxc67dj47i2s7vr0
30 Oct 20
Ligand Reports Third Quarter 2020 Financial Results
8:03am
8-K
EX-2.1
230fj2d
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
igvuj2 sp7
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-99.1
b5o3q3qwlvqlyoi
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-99.1
o6pbk8zi8s 4gu0t4
1 Oct 20
Contingent Value Rights Agreement
8:42am
8-K
EX-99.3
y8vnc7uglxrgbhjz7e
1 Oct 20
Contingent Value Rights Agreement
8:42am
SC TO-T/A
EX-99
q4dsrsy3
30 Sep 20
Third party tender offer statement (amended)
8:06am
SC TO-T/A
ibydc pgi
16 Sep 20
Third party tender offer statement (amended)
6:05am
SC TO-T/A
iek92xe slsyb
11 Sep 20
Third party tender offer statement (amended)
6:07am